Netherlands-based venture capital firm BioGeneration Ventures (BGV) closed its third fund at €82m ($95.5m) today, having secured capital from limited partners including pharmaceutical firms Bristol-Myers Squibb and Johnson & Johnson (J&J).

The fund’s LPs also include European Investment Fund (EIF), private equity firm Schroder Adveq, and Man Pension Trust, which manages the pension funds of mechanical engineering firm Man’s employees. J&J invested through its Johnson & Johnson Innovation – JJDC unit.

BGV III seeks to identify early-stage opportunities in the…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?